Biopartner 3, Galileiweg 8, 2333 BD Leiden, The Netherlands
Updates from our team, science, and community.
June 2026
We will be at the BIO International Convention in San Diego, June 22 to 25, the largest biotech partnering event of the year. If you work on diabetes, metabolic disease, drug safety, or gene therapy and want to see what human 3D microtissues can do for your program, let's meet. Book a slot through BIO One-on-One Partnering, or reach out directly and we will find a time.
May 2026
It is always good to meet our partners in person and catch up on a personal level, not just over email and calls. We had a few good days at Future Labs Live in Basel doing exactly that, with our development partner and the wider community. As ever, some of the best of it happened over lunch.
May 2026
We spent an afternoon at BioPartner Leiden with students who are still working out what kind of scientist they want to be. Thanks to PLNT Leiden and the L.P.S.V. Aesculapius team for having us, and to the students for the sharp questions. Sharing what it takes to build a biotech and move a technology from the lab toward industry is one of the more rewarding parts of this work.
February 12, 2026
We joined the DCVA & RegMed XB Community Event at Grand Hotel Karel V in Utrecht as part of the Springboard programme. Pitching to the regenerative medicine community in the Netherlands, connecting with clinicians, investors, and fellow cell and gene therapy teams working across the ecosystem.
February 6, 2026
We expanded our Leiden lab with confocal imaging and flow cytometry capabilities. A direct response to what clients have been asking for: deeper, multi-parameter readouts on our human microtissue assays, covering viability, phenotype, and function beyond GSIS. The infrastructure is in place to support programs that need more than a single readout.
February 2026
StemX Bio has been awarded the KvW Innovation Voucher under the Leiden Bio Science Park. This funding supports our participation in the unlock_ incubation program, focusing on strategic coaching and commercial development. As we advance our 3D pancreatic microtissue technology to improve diabetes drug discovery, validating our business model is just as critical as validating our science.
December 2025
StemX Bio won the "Startup in Absence" award at the annual Golden PLNT Awards. The event is an end-of-year celebration organized by PLNT for its community, featuring fun awards and a mystery-play format. We earned the title after renting office space at PLNT for a few months in 2025 before moving to our permanent lab at Biopartner 3.
November 2025
Our team attended BIO-Europe 2025 in Vienna, Austria (November 3-5). The conference brought together 5,700+ participants from 2,900 companies. We connected with pharma and biotech leaders about pilots, co-development, and CRO collaborations for our microtissue platform.
October 2025
StemX Bio secured pre-seed funding from UNIIQ to accelerate market entry. The investment supports our exclusive IP license from LUMC and the development of our iPSC-derived microtissue platform. This funding, combined with grants from MIT Feasibility, Proefdiervrij, and LEH, positions us to bring our technology to pharma and biotech clients.
September 2025
In just one year, we set up our own lab in Leiden, achieved our first exciting results, and kicked off 5 collaborations. Jane and Elena took a moment to celebrate and reflect on how far we have come as co-founders and everything that is next.
July 5, 2025
We opened our Biopartner 3 lab for the Leiden Bio Science Park Open Day, co-hosted with Johnson & Johnson. A full afternoon of visitors, questions, and conversations across the park (pioneer and start-up side by side), showing what makes this ecosystem work.
May 20, 2025
Annual portfolio gathering at the Pesthuis in Leiden, hosted by Libertatis Ergo Holding (LEH), one of our first institutional backers. Good evening catching up with fellow portfolio CEOs and the LEH team.
March 2025
Our team attended ATTD 2025 (Advanced Technologies and Treatments for Diabetes) in Amsterdam, connecting with researchers and companies working in diabetes technology and therapeutics.
February 2025
StemX Bio was selected as a finalist in the Gulliver Startup Competition at Leiden Bio Science Park. The competition, held at the Pesthuis in Leiden, brings together early-stage life sciences companies to present their work and compete for a prize of 10,000 euros.
September 2024
StemX Bio B.V. was founded by Elena Naumovska and Jane Spirkoski in Leiden, The Netherlands. The company was established to commercialize Elena's proprietary technology for producing 3D human microtissues from iPSC differentiation.
April 2024
StemX Bio was one of four teams selected for the Proefdiervrij Venture Challenge 2024. Our fully chemical, animal-free stem cell differentiation method has the potential to reduce animal use in drug testing by 90%.
TNO Fast Track · 2025
Accelerating diabetes drug discovery →
How StemX Bio creates mini pancreases from stem cells in 15 days. Partnership with TNO for 384-well plate design.
MT/Sprout · March 2026
Atlanta is voor startups 60 procent goedkoper →
Jane quoted on US market opportunities for StemX Bio's animal-free testing platform.
InnovationQuarter · October 2025
Smarter manufacturing and faster drug development thanks to StemX Bio →
UNIIQ invests 350K in StemX Bio. Covers the exclusive IP license from LUMC and plans for market entry.
Silicon Canals · October 2025
Two South Holland startups secure investment from UNIIQ →
Tech media coverage of the pre-seed round and supplementary grants.
LURIS · 2026
Re-engineering the pancreas in 3D: how StemX Bio is reshaping diabetes research →
Feature article on StemX Bio's technology, LUMC roots, and UNIIQ investment. Includes quotes from Jane on the company's mission.
Proefdiervrij · 2024
Teams of the Proefdiervrij Venture Challenge 2024 →
StemX Bio selected as one of four teams. Chemical, animal-free differentiation reducing testing by 90%.
